Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: standard of care topical gel Clear all
Completed Not applicable Interventional

Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections

NCT01886001
View directory record Official record
Conditions
Colonization
Interventions
Povidone-Iodine, Chlorhexidine, Pluronic, Control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 7 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 29, 2026, 5:09 AM EDT
Terminated Phase 4 Interventional Results available

Superficial Partial-Thickness Burn Study

NCT04601532
View directory record Official record
Conditions
Superficial Partial Thickness Burn
Interventions
Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine
Device · Drug
Lead sponsor
J. Peter Rubin, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 29, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

NCT07630155
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Analgesic Agent, Electronic Health Record Review, Lidocaine Topical, Medical Device Usage and Evaluation, Survey Administration, Ureteroscopy
Drug · Other · Device + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis

NCT01471457
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Trimo-San gel
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT02733432
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 4 Interventional

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044
View directory record Official record
Conditions
Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions
Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 29, 2026, 5:09 AM EDT
Withdrawn Not applicable Interventional

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT05106192
View directory record Official record
Conditions
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma, Lymphomatoid Papulosis, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Follicular
Interventions
Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel, Nitrogen Mustard, Conventional syringe
Device · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 29, 2026, 5:09 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effectiveness of Synapse Transcutaneous Electronic Nerve Stimulation (TENS) During Dental Procedures Among Children

NCT03779659
View directory record Official record
Conditions
Dental Fear, Anesthesia, Local, Pediatric Dentistry
Interventions
Synapse TENS device, Topical anesthetic gel
Device · Drug
Lead sponsor
Boston University
Other
Eligibility
6 Years to 14 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051
View directory record Official record
Conditions
Diabetic Foot
Interventions
GAM501, Placebo, Standard of care
Biological · Other
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

NCT00027248
View directory record Official record
Conditions
Sepsis, Bacteremia, Fungemia
Interventions
MBI 226
Drug
Lead sponsor
BioWest Therapeutics Inc
Industry
Eligibility
16 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lake Bluff, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Internet Surveys and Their Impact on Adherence for Rosacea

NCT03048058
View directory record Official record
Conditions
Rosacea
Interventions
brimonidine topical gel 0.33% & survey, brimonidine topical gel 0.33% & SOC
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Beta Adrenergic Antagonist for the Healing of Chronic DFU

NCT03282981
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
Interventions
Timolol, Non biologically active gel
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 29, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

NCT05930210
View directory record Official record
Conditions
Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Interventions
ENERGI-F703 GEL, ENERGI-F703 matched vehicle
Drug
Lead sponsor
Energenesis Biomedical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Palmetto Bay, Florida • Columbus, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 29, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

Tissue Repair Gel in Venous Leg Ulcers (US)

NCT06707090
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wounds, Venous Insufficiency of Leg, Non-healing Wound
Interventions
TR987 0.1% gel + Standard of Care, Standard of care
Drug · Other
Lead sponsor
TR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Castro Valley, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

NCT01874860
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid)
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 29, 2026, 5:09 AM EDT
Terminated Phase 3 Interventional

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

NCT02667327
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Granexin gel, Vehicle gel
Drug · Other
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Doral, Florida • Hialeah, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 29, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Pain Control for Cervical Ripening Balloon

NCT07268118
View directory record Official record
Conditions
Labor Induction
Interventions
topical vaginal application lidocaine gel
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 29, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

Tissue Repair Gel in Venous Leg Ulcers in AU/US

NCT06707103
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wound, Venous Insufficiency of Leg, Non-healing Wound
Interventions
TR987 0.1% gel + Standard of Care, Standard of care
Drug · Other
Lead sponsor
TR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Jacksonville, Florida • Clinton Twp, Michigan • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 29, 2026, 5:09 AM EDT
Terminated Phase 4 Interventional Results available

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

NCT04200651
View directory record Official record
Conditions
Glaucoma, Cataract
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The New York Eye Surgery Center
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 29, 2026, 5:09 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566
View directory record Official record
Conditions
Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Ibuprofen 600 mg, Education
Drug · Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds

NCT00971048
View directory record Official record
Conditions
Diabetic Foot Ulcers, Pressure Ulcers
Interventions
HP828-101, Hydrogel/Hydrocolloid
Device
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Bakersfield, California • Chula Vista, California • Fresno, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 29, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers

NCT02652572
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Granexin
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Augusta, Georgia • Spartanburg, South Carolina • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 29, 2026, 5:09 AM EDT
Recruiting Phase 4 Interventional

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT04371445
View directory record Official record
Conditions
Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 29, 2026, 5:09 AM EDT